Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan 1;18(1):11-13.
doi: 10.2215/CJN.0000000000000028.

Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?

Erum A Hartung  1   2
Affiliations
Comment

Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?

Erum A Hartung. Clin J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

E.A. Hartung reports having advisory or leadership roles for Polycystic Kidney Disease Foundation—Scientific Advisory Committee and PKD in Children Council/ARPKD Task Force, serving as a member of the American Society of Pediatric Nephrology, and serving as a Nephrology Subboard Member of the American Board of Pediatrics.

Figures

Figure 1
Figure 1
Estimations of the benefit of tolvaptan in delaying kidney failure. Extrapolations from the TEMPO 3:4 (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial allow estimations of the potential benefit of tolvaptan treatment in delaying the need of KRT depending on the eGFR at baseline. Tolvaptan might delay reaching stage 5 CKD by 7.3, 4.4, 2.9, or 1.5 years if baseline eGFR was 90, 60, 45, or 30 ml/min, respectively. These extrapolations are made using the average decline in eGFR between placebo (−3.7 ml/min per year) and tolvaptan (−2.72 ml/min per year) groups in the TEMPO 3:4 trial. Adapted from ref. 4, with permission.
See this image and copyright information in PMC

Comment on

References

    1. De Rechter S, Breysem L, Mekahli D. Is autosomal dominant polycystic kidney disease becoming a pediatric disorder? Front Pediatr. 2017;5:272. doi:10.3389/fped.2017.00272 - DOI - PMC - PubMed
    1. Benz EG, Hartung EA. Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2021;36(9):2639-2658. doi:10.1007/s00467-020-04869-w - DOI - PMC - PubMed
    1. Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B. Long-term outcomes in patients with very-early onset autosomal dominant polycystic kidney disease. Am J Nephrol. 2016;44(3):171-178. doi:10.1159/000448695 - DOI - PMC - PubMed
    1. Chebib FT Perrone RD Chapman AB, et al. . A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-2470. doi:10.1681/ASN.2018060590 - DOI - PMC - PubMed
    1. Irazabal MV Rangel LJ Bergstralh EJ, et al. . Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160-172. doi:10.1681/ASN.2013101138 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources